Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer.

J. Buter,R. Janssen,A. Martens,D. Sleijfer,L. de Leij,N. Mulder
DOI: https://doi.org/10.1016/0959-8049(93)90044-G
IF: 10.002
European Journal of Cancer
Abstract:
What problem does this paper attempt to address?